Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.
PMID 19812598 · PMC2825112 · The Journal of investigative dermatology · 2010 · 8 claims · 5 setups
EGFR is activated by somatic mutation in a small subset of cutaneous SCC
-
Full-text index only
p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status.
PMID 8142262 · PMC1968818 · British journal of cancer · 1994 · 7 claims · 6 setups
Somatic mutation in the p53 gene hotspot regions occurs infrequently in cervical carcinomas
-
Full-text index only
Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction.
PMID 12877750 · PMC183853 · BMC biotechnology · 2003 · 6 claims · 5 setups
Polony technology can detect intragenic mutations in well-defined hotspots of p53 (codons 175, 245, 248, 249, 273, 282) and K-ras2 (codons 12, 13, 61)
-
Full-text index only
Absence of the TAP2 human recombination hotspot in chimpanzees.
PMID 15208713 · PMC423135 · PLoS biology · 2004 · 6 claims · 7 setups
The human TAP2 recombination hotspot is absent from the homologous region in western chimpanzees.
-
Full-text index only
K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients.
PMID 18957720 · PMC3827803 · Disease markers · 2008 · 8 claims · 6 setups
P53 mutations were identified in 34.4% of NSCLC tumours, most frequently in SCC (55.6%)
-
Full-text index only
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
PMID 17668422 · PMC2443273 · The Journal of pathology · 2007 · 8 claims · 4 setups
FGFR3 mutations occur in 42% of primary urothelial carcinomas and are significantly associated with low tumour grade and stage
-
Full-text index only
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
PMID 17912529 · PMC4876910 · World journal of urology · 2007 · 8 claims · 8 setups
Activating FGFR3 mutations occur frequently in bladder cancer and are strongly associated with low tumour grade and stage
-
Full-text index only
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
PMID 19010816 · PMC6953412 · Molecular cancer research : MCR · 2008 · 8 claims · 8 setups
Activating RAS-MAPK pathway mutations are present in >70% of serous LMP tumors versus ~12.5% of serous ovarian carcinomas